Papillomavirus probe and process for in vitro diagnosis of papillomavirus infections

• US 5,712,092 A
• Filed: 07/14/1994
• Issued: 01/27/1998
• Est. Priority Date: 11/30/1984
• Status: Expired due to Term

• Current Assignee: Roche Molecular Systems Inc (Roche Holding AG)
• Original Assignee: Institut National De La Sante Et De La Recherche Medicale (Inserm) (Allianz Global Investors GmbH), Institut Pasteur
• Inventors: Kremsdorf, Dina, Beaudenon, Sylvie, Croissant, Odile, Orth, Gerard, Pehau-Arnaudet, Gerard, Favre, Michel
• Primary Examiner(s): Jones, W. Gary
• Assistant Examiner(s): TRAN, PAUL
• Application Number:
  US08/274,159
• Time in Patent Office: 1,293 Days
• Field of Search: 435/6, 435/5, 435/252.3, 435/948, 435/320.1, 536/23.72, 536/24.3, 536/24.32
• US Class Current: 435/6.12
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12Q 1/708 for papilloma

Abstract

The invention relates to human papillomaviruses HPV, particularly to HPV-DNAs isolated from papillomaviruses HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b, HPV-19, HPV-20, HPV-21, HPV-22, HPV-23, HPV-24, HPV-28, HPV-29, HPV-31, HPV-32, HPV-IP2 and HPV-IP4. The invention also relates to DNA capable of hybridizing with the HPV-DNAs or fragments thereof, to kits containing distinct groups of probes containing one or more of these HPV-DNAs or fragments thereof, and to procedures for detecting and identifying HPV in tissue.

Claims

1. Isolated DNA of a human papillomavirus (HPV), wherein said DNA is about 7,000 to about 8,000 base pairs;

and

said DNA is obtained from a virus selected from the group consisting of HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b, HPV-19, HPV-20, HPV-21, HPV-22, HPV-23, HPV-24, HPV-28, HPV-29, HPV-31, HPV-32, HPV-IP2, and HPV-IP4.

2. DNA according to claim 1, wherein said DNA consists of a gene of said HPV DNA, and wherein said gene is selected from the group of genes consisting of E1, E6-E7, L1, and L2.

3. DNA according to claim 1, wherein said DNA corresponds to a segment of human papillomavirus (HPV) DNA located between genes of the HPV.

4. Recombinant human papillomavirus (HPV) DNA comprising DNA according to claim 1.

5. A probe for the detection of human papillomavirus (HPV) DNA, said probe comprising HPV DNA or recombinant HPV DNA, according to claim 1.

6. A mixture of human papillomavirus (HPV) DNA, wherein said mixture comprises

human papillomavirus (HPV) DNA according to claim 1;

and

at least one additional human papillomavirus (HPV) DNA that is different from the HPV DNA of claim 1.

7. A process for the detection and identification of papillomavirus in a biological sample, said process comprising:

performing hybridization assays with one or more human papillomavirus (HPV) DNAs or fragments thereof as claimed in claim 1; and

detecting the resultant hybridized HPV DNA or fragments thereof.

8. A diagnostic kit comprising one or more human papillomavirus (HPV) probes, wherein said kit contains the following groups of probes:

(1) the HPV DNA of HPV-2d;

(2) at least one of the HPV DNAs of HPV-10b, HPV-28, and HPV-29;

(3) at least one of the HPV DNAs of HPV-17 and HPV-24;

(4) at least one of the HPV DNAs of HPV-14, HPV-15, HPV-17, HPV-19, HPV-20, HPV-21, HPV-22, and HPV-23;

(5) at least one of the HPV DNAs of HPV-15 and HPV-17;

(6) the HPV DNA of HPV-24;

(7) at least one of the HPV DNAs of HPV-14 and HPV-32;

(8) the HPV DNA of HPV-31;

(9) the HPV DNA of HPV-32;

wherein the human papillomavirus (HPV) DNA of the groups is chosen such that if each of the nine groups contains only one HPV DNA group member, the HPV DNA of each of the nine groups will be different from each other.

9. A diagnostic kit comprising one or more human papillomavirus (HPV) probes, wherein said kit contains the following groups of probes:

(1) the HPV DNA of HPV-2d;

(2) at least one of the HPV DNAs of HPV-10b, HPV-28, and HPV-29;

(3) at least one of the HPV DNAs of HPV-17 and HPV-24;

(4) at least one of the HPV DNAs of HPV-14, HPV-15, HPV-17, HPV-19, HPV-20, HPV-21, HPV-22, and HPV-23;

(5) at least one of the HPV DNAs of HPV-15 and HPV-17;

(6) the HPV DNA of HPV-24;

(7) at least one of the HPV DNAs of HPV-14 and HPV-32;

(8) the HPV DNA of HPV-31;

(9) the HPV DNA of HPV-32;

(10) at least one of the HPV DNAs of HPV-16, HPV-18, and HPV-IP2;

wherein the HPV DNA of the groups is chosen such that if each of the ten groups contains only one HPV DNA group member, the HPV-DNA of each of the ten groups will be different from each other.

10. An isolated DNA, wherein said DNA is selected from the group consisting of

(a) HPV-2d DNA between the restriction sites shown in FIG. 1;

(b) HPV-10b DNA between the restriction sites shown in FIG. 2;

(c) HPV-14a DNA between the restriction sites shown in FIG. 4a;

(d) HPV-14b DNA between the restriction sites shown in FIG. 4a;

(e) HPV-15 DNA between the restriction sites shown in FIG. 5;

(f) HPV-17a DNA between the restriction sites shown in FIG. 5;

(g) HPV-17b DNA between the restriction sites shown in FIG. 5;

(h) HPV-19 DNA between the restriction sites shown in FIG. 4b;

(i) HPV-20 DNA between the restriction sites shown in FIG. 4b;

(j) HPV-21 DNA between the restriction sites shown in FIG. 4b;

(k) HPV-22 DNA between the restriction sites shown in FIG. 4b;

(l) HPV-23 DNA between the restriction sites shown in FIG. 4b;

(m) HPV-24 DNA between the restriction sites shown in FIG. 6;

(n) HPV-28 DNA between the restriction sites shown in FIG. 2;

(o) HPV-29 DNA between the restriction sites shown in FIG. 2;

(p) HPV-31 DNA between the restriction sites shown in FIG. 8;

(q) HPV-32 DNA between the restriction sites shown in FIG. 7;

(r) HPV-IP2 DNA between the restriction sites shown in FIG. 9; and

(s) HPV-IP4 DNA between the restriction sites shown in FIG. 9,

and DNA complementary to any one of said DNAs.

11. The plasmid pBR322/HPV2d.

12. Human papillomavirus DNA contained in C.N.C.M. (Collection Nationale de Culturae de Microorganisms) Accession No. I-379.

13. A process for producing a human papillomavirus (HPV) DNA probe, wherein said probe comprises DNA of a human papillomavirus (HPV), wherein

(1) said DNA is about 7,000 to about 8,000 base-pairs;

(2) said DNA is obtained from the group of papillomaviruses consisting of HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b, HPV-19, HPV-20, HPV-21, HPV-22, HPV-23, HPV-24, HPV-28, HPV-29, HPV-31, HPV-32, HPV-IP2, and HPV-IP4, said process comprising

(A) producing a recombinant vector comprising said DNA of a HPV and a suitable vector, wherein said HPV DNA is inserted into said vector at a site permitting the subsequent cloning of said recombinant vector into a suitable host;

(B) cloning said recombinant vector into a suitable host; and

(C) recovering the resultant cloned recombinant HPV DNA.

14. The process according to claim 13, wherein said host is a procaryotic microorganism.

15. The process according to claim 13, wherein said recombinant vector comprises the complete DNA sequence of a human papillomavirus (HPV).

16. The process according to claim 13, wherein said recombinant vector comprises a fragment complete DNA sequence of a human papillomavirus (HPV).

17. The process according to claim 13, wherein said process further comprises labeling the resultant cloned recombinant HPV DNA with a marker selected from the group consisting of an enzyme, a radioactive compound, and a fluorescent compound.